DHR vs IQV
Danaher Corporation and IQVIA, both Healthcare
Danaher Corporation is the larger company at $156B against $43B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.5 against 39.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +40% against +15% for DHR. The RyuScore puts IQV ahead, 66 against 48 out of 100.
| Figure | DHR | IQV |
|---|---|---|
| Last close | $221 | $262 |
| Market cap | $156B | $43B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 39.3 | 32.5 |
| 1-year return | +15% | +40% |
| 5-year return | -21% | +1.8% |
| RyuScoresector-relative, 1–10 | 48/100 | 66/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Danaher Corporation
Revenue of $6.3B in Q2 2026, net income $870M. Its largest reported line is Diagnostics, 46% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.